Nox4 inhibition enhances the cytotoxicity of cisplatin in human renal cancer cells

Journal of Experimental Therapeutics and Oncology

Volumn 10, Issue 1, 2012, Pages 9-18

  Chang, Guimin ^a   Chen, Li ^a   Lin, Hui Min ^b   Lin, Yan ^b   Maranchie, Jodi K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemosensitivity; Cisplatin; Nox4; Renal cell carcinoma; Superoxide

Indexed keywords

CISPLATIN; DIPHENYLIODONIUM SALT; DITHIOTHREITOL; DOXORUBICIN; ETOPOSIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; SUPEROXIDE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; NADPH OXIDASE; REACTIVE OXYGEN SPECIES;

EID: 84864408121     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL, and Simon MC. HIF-2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 106: 14391-14396, 2009.
2. Block K, Gorin Y, Hoover P, Williams P, Chelmicki T, Clark RA, Yoneda T, and Abboud HE. NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem 282: 8019-8026, 2007. (Pubitemid 47093603)
3. Clement MV, Ponton A, and Pervaiz S. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett 440: 13-18, 1998. (Pubitemid 28558725)
4. Diebold I, Flugel D, Becht S, Belaiba RS, Bonello S, Hess J, Kietzmann T, and Gorlach A. The Hypoxia-inducible Factor-2alpha Is Stabilized by Oxidative Stress Involving NOX4. Antioxid Redox Signal.
5. Ferguson RE, Jackson SM, Stanley AJ, Joyce AD, Harnden P, Morrison EE, Patel PM, Phillips RM, Selby PJ, and Banks RE. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 115: 155-163, 2005. (Pubitemid 40559682)
6. Gill PS, and Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 8: 1597-1607, 2006. (Pubitemid 44726334)
7. Jemal A, Center MM, DeSantis C, and Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
8. Krause KH. Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 57: S28-29, 2004.
9. Lee S, Moon SO, Kim W, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Lee SY, and Park SK. Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol Dial Transplant 21: 2085-2095, 2006. (Pubitemid 44295033)
10. Li D, Ueta E, Kimura T, Yamamoto T, and Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 95: 644-650, 2004. (Pubitemid 39255811)
11. Loboda A, Jozkowicz A, and Dulak J. HIF-1 and HIF-2 transcription factors - similar but not identical. Molecules and cells 29: 435-442.
12. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, and Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255, 2002. (Pubitemid 41039149)
13. Maranchie JK, and Zhan Y. Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res 65: 9190-9193, 2005. (Pubitemid 41507983)
14. Mertins SD, Myers TG, Hollingshead M, Dykes D, Bodde E, Tsai P, Jefferis CA, Gupta R, Linehan WM, Alley M, and Bates SE. Screening for and identification of novel agents directed at renal cell carcinoma. Clin Cancer Res 7: 620-633, 2001. (Pubitemid 32707988)
15. Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, Hirose K, Kiyosawa K, and Kamata T. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 25: 3699-3707, 2006. (Pubitemid 43980491)
16. Mohazzab KM, and Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. The American journal of physiology 267: L815-822, 1994.
17. Motzer RJ, and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163: 408-417, 2000. (Pubitemid 30060482)
18. Naito S, Koga H, Yokomizo A, Sakamoto N, Kotoh S, Nakashima M, Kiue A, and Kuwano M. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World journal of surgery 24: 1183-1186, 2000.
19. Nomura M, Matsunami T, Kobayashi K, Uchibayashi T, Koshida K, Tanaka M, Namiki M, Mizuhara Y, Akiba T, Yokogawa K, Moritani S, and Miyamoto K. Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin. Anticancer Res 25: 2729-2735, 2005.
20. Pervaiz S, and Clement MV. Superoxide anion: oncogenic reactive oxygen species? The international journal of biochemistry & cell biology 39: 1297-1304, 2007.
21. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, and Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686, 2005. (Pubitemid 40853601)
22. Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Current oncology reports 8: 85-89, 2006.
23. Rivera-Nieves J, Thompson WC, Levine RL, and Moss J. Thiols mediate superoxide-dependent NADH modification of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 274: 19525-19531, 1999.
24. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, and Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 69: 9056-9064, 2009.
25. Sandusky GE, Mintze KS, Pratt SE, and Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41: 65-74, 2002. (Pubitemid 34779683)
26. Shono T, Yokoyama N, Uesaka T, Kuroda J, Takeya R, Yamasaki T, Amano T, Mizoguchi M, Suzuki SO, Niiro H, Miyamoto K, Akashi K, Iwaki T, Sumimoto H, and Sasaki T. Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int J Cancer 123: 787-792, 2008. (Pubitemid 352032403)
27. Streibig JC, and Ritz C. Bioassay Analysis Using R. Journal of Statistical Software 12: 1-22, 2005. (Pubitemid 40218001)
28. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, and Huang P. Redox regulation of cell survival. Antioxid Redox Signal 10: 1343-1374, 2008.
29. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, and Gukovskaya AS. Reactive oxygen species produced by NAD(P) H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 279: 34643-34654, 2004. (Pubitemid 39318094)
30. Wangila GW, Nagothu KK, Steward R, 3rd, Bhatt R, Iyere PA, Willingham WM, Sorenson JR, Shah SV, and Portilla D. Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper(2)(II)(3,5-ditertiarybutylsalicylate)(4)(ethanol)(4)]. Toxicol In Vitro 20: 1300-1312, 2006.